Evidence map›Paper›PMID 33137341›Full record

ArticleKidney international2020

IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT).

Olivier Thaunat, Camille Legeai, Dany Anglicheau, Lionel Couzi, Gilles Blancho, Marc Hazzan, Myriam Pastural, Emilie Savoye, Florian Bayer, Emmanuel Morelon and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Kidney international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. COVID-19 and solid organ transplantation: Finding the right balance.Transplantation reviews (Orlando, Fla.) · 2022
    Pooled it
  2. Article
  3. Comparable outcomes with anti-thymocyte globulins versus basiliximab in kidney transplantation from controlled circulatory death donors.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Results of the first nationwide cohort study of outcomes in dialysis and kidney transplant patients before and after vaccination for COVID-19.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  10. Article
  11. Protective Effect of Vaccine Doses and Antibody Titers Against SARS-CoV-2 Infection in Kidney Transplant Recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Olivier ThaunatLyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France; Hospices Civils de Lyon, Edouard Herriot Hospital, Department of Transplantation, Nephrology and Clinical Immunology, Lyon, France; CIRI, INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University Lyon, 21, Lyon, France. Electronic address: olivier.thaunat@chu-lyon.fr.
Camille LegeaiAgence de la Biomédecine, Saint Denis la Plaine, France.
Dany AnglicheauDepartment of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Lionel CouziDepartment of Nephrology and Transplantation, University of Bordeaux, Bordeaux, France.
Gilles BlanchoInstitut de Transplantation-Urologie-Néphrologie (ITUN), CHU Nantes, France; Centre de Recherche en Transplantation et Immunologie, UMR 1064 Inserm, Université de Nantes, Nantes, France.
Marc HazzanUniversity Lille, Inserm, CHU Lille, U1286-Infinite-Institute for Translational Research in Inflammation, Lille, France.
Myriam PasturalAgence de la Biomédecine, Saint Denis la Plaine, France.
Emilie SavoyeAgence de la Biomédecine, Saint Denis la Plaine, France.
Florian BayerAgence de la Biomédecine, Saint Denis la Plaine, France.
Emmanuel MorelonLyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France; Hospices Civils de Lyon, Edouard Herriot Hospital, Department of Transplantation, Nephrology and Clinical Immunology, Lyon, France; CIRI, INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University Lyon, 21, Lyon, France.
Yann Le MeurDepartment of Nephrology and Transplantation, University of Brest, Brest, France.
Olivier BastienAgence de la Biomédecine, Saint Denis la Plaine, France.
Sophie CaillardDepartment of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France.
French nationwide Registry of Solid Organ Transplant Recipients with COVID-19
Agence de la Biomédecine · FRInserm · FRUniversité Claude Bernard Lyon 1 · FRAssistance Publique – Hôpitaux de Paris · FRUniversité de Bordeaux · FRUniversité de Bretagne Occidentale · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

End stage kidney disease increase the risk of COVID-19 related death but how the kidney replacement strategy should be adapted during the pandemic is unknown. Chronic hemodialysis makes social distancing difficult to achieve. Alternatively, kidney transplantation could increase the severity of COVID-19 due to therapeutic immunosuppression and contribute to saturation of intensive care units. For these reasons, kidney transplantation was suspended in France during the first epidemic wave. Here, we retrospectively evaluated this strategy by comparing the overall and COVID-19 related mortality in kidney transplant recipients and candidates over the last three years. Cross-interrogation of two national registries for the period 1 March and 1 June 2020, identified 275 deaths among the 42812 kidney transplant recipients and 144 deaths among the 16210 candidates. This represents an excess of deaths for both populations, as compared with the same period the two previous years (mean of two previous years: 253 in recipients and 112 in candidates). This difference was integrally explained by COVID-19, which accounted for 44% (122) and 42% (60) of the deaths in recipients and candidates, respectively. Taking into account the size of the two populations and the geographical heterogeneity of virus circulation, we found that the excess of risk of death due to COVID-19 was similar for recipients and candidates in high viral risk area but four-fold higher for candidates in the low viral risk area. Thus, in case of a second epidemic wave, kidney transplantation should be suspended in high viral risk areas but maintained outside those areas, both to reduce the excess of deaths of candidates and avoid wasting precious resources.

Indexed as

RegistriesAdultAgedAged, 80 and overCOVID-19EpidemicsFemaleFranceHumansKidney TransplantationMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesWaiting ListsCOVID-19ESRDmortalityrenal transplantationSARS-CoV-2

Identifiers

PMID33137341
PMCPMC7604114
OpenAlexW3094775035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.